Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Alexza Pharmaceuticals, Inc. |
---|---|
Information provided by: | Alexza Pharmaceuticals, Inc. |
ClinicalTrials.gov Identifier: | NCT00874237 |
The purpose of the present Phase 1 study is to assess the cardiac safety of Staccato Loxapine administered to healthy volunteers in a 3 period crossover study.
Condition | Intervention | Phase |
---|---|---|
Healthy |
Drug: 1 (Staccato Loxapine) Drug: 2 (Moxifloxacin) Drug: 3 (Placebo) |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Crossover Assignment, Safety Study |
Official Title: | Thorough QT/QTc Study of Staccato® Loxapine for Inhalation in Healthy Volunteers |
Estimated Enrollment: | 48 |
Study Start Date: | April 2009 |
Estimated Study Completion Date: | June 2009 |
Estimated Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Staccato Loxapine
|
Drug: 1 (Staccato Loxapine)
Staccato Loxapine
|
2: Active Comparator
Oral moxifloxacin
|
Drug: 2 (Moxifloxacin)
Oral moxifloxacin
|
3: Placebo Comparator
Placebo
|
Drug: 3 (Placebo)
Placebo
|
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contact: Robert S. Fishman, MD | 650 944 7000 | rfishman@alexza.com |
Contact: Laura E. Mei | 650 944 7474 | lmei@alexza.com |
United States, Indiana | |
Covance Clinical Research Unit Inc. | Recruiting |
Evansville, Indiana, United States, 47710 | |
Contact: Randall R. Stoltz, MD 812-469-5000 randall.stoltz@covance.com | |
Contact: Angela Ashbrook, BS 812 469 5036 angela.ashbrook@covance.com | |
Principal Investigator: Randall R. Stoltz, MD |
Principal Investigator: | Randall R. Stoltz, MD | Covance Clinical Research Unit Inc. |
Responsible Party: | Alexza Pharmaceuticals, Inc. ( Robert Fishman, MD ) |
Study ID Numbers: | AMDC-004-107, February 26, 2009 |
Study First Received: | April 1, 2009 |
Last Updated: | April 1, 2009 |
ClinicalTrials.gov Identifier: | NCT00874237 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Staccato loxapine QTc healthy volunteers |
Neurotransmitter Agents Dopamine Tranquilizing Agents Moxifloxacin Psychotropic Drugs |
Loxapine Central Nervous System Depressants Dopamine Agents Healthy Antipsychotic Agents |
Anti-Infective Agents Neurotransmitter Agents Tranquilizing Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Central Nervous System Depressants Dopamine Antagonists |
Antipsychotic Agents Pharmacologic Actions Moxifloxacin Therapeutic Uses Loxapine Dopamine Agents Central Nervous System Agents |